Development of bifunctional anti-PD-L1 antibody MMAE …
Nov 1, 2021 · A bifunctional PD-L1-ADC was developed based on the use of endocytic PD-L1 antibody Atezolizumab, exhibiting potent cytotoxicity (EC50 = 9.75 ∼ 11.94 nM) and immune …
Development of PD-L1 Antibody Drug Conjugates (ADC)
Aug 26, 2022 · SGN-PDL1V is a PD-L1-directed ADC currently under preclinical investigation that consists of an anti-PD-L1 antibody conjugated to a vedotin drug ligand. The vedotin drug linker …
Antibody-drug conjugates in breast cancer: current evidence and …
Mar 20, 2025 · The combination of an ADC and a programmed death-1 (PD-1)/PD-L1 inhibitor has been a promising treatment regimen for TNBC. In the phase 2 platform sequential multiple …
Identification of a hotspot on PD-L1 for pH-dependent binding by ...
Aug 24, 2020 · PD-L1 antibody drug conjugate (ADC) for selective chemo-guided immune modulation of tumor has also been developed which has shown promising tumor suppression …
Global Second PD-L1 ADC: Henlius’ HLX43, a Novel PD-L1 ADC, …
Feb 20, 2025 · Pfizer’s PD-L1 ADC, SGN-PDL1V, is currently leading the field, with plans to initiate a pivotal Phase 3 clinical trial for first-line treatment of head and neck squamous cell …
Novel bispecific antibody-drug conjugate targeting PD-L1 and B7 …
This BsADC selectively targets the immune checkpoints programmed cell death ligand-1 (PD-L1) and B7-H3, and the precise delivery of the small-molecule toxin monomethyl auristatin E. …
693P Preclinical activity of HLX43, a PD-L1-targeting ADC, in …
HLX43 is a novel PD-L1-targeting ADC consisting of an engineered anti-PD-L1 humanised IgG1 antibody linked to a camptothecin-based toxin, with a drug to antibody ratio of 8. Our …
PD-L1-directed Antibody Drug Conjugate - Pfizer Oncology …
The proposed MOAs of PDL1V reflect the hallmarks of vedotin-based ADCs: MMAE-induced cytotoxicity against PD-L1-expressing tumor cells, immunogenic cell death (ICD), and …
The effectiveness and safety of RC48 alone or in combination with PD …
Feb 28, 2025 · PD-L1 expression in tumor samples was assessed by the Ventana PD-L1 Assay (SP263, Ventana Medical Systems, Inc.). ... Zhou L, et al. RC48-ADC combined with …
Pfizer's PD-L1 Antibody-Drug Conjugate Demonstrates …
Sep 13, 2024 · Pfizer subsidiary Seagen is developing the PD-L1-directed ADC, dubbed SGN-PDL1V or PF-0804605. The drug comprises a PD-L1 monoclonal antibody attached to the …
- Some results have been removed